ClinPhone Opens New Paris Office
ClinPhone strengthens its presence in Europe with the opening of a new Paris office.
Nottingham UK-May 15, 2008-ClinPhone (www.clinphone.com), the world’s largest Clinical Technology Organization (CTO), announced the opening of its new Paris office, further increasing its presence in this geographic region. The office opening was marked by an opening ceremony at Le Train Bleu, Place Louis Armand, Paris. The invitation-only event was attended by ClinPhone staff, clients and partners.
ClinPhone already has a number of large pharmaceutical clients based in France that have benefited from using ClinPhone’s clinical technologies. This new office will provide both its current and new customers within this region with a local point of contact.
Damien Tremolet, director of operations at ClinPhone, will lead the new office, which is centrally located in the business center of the Gare de Lyon station in Paris, France. He will be supported by Jacques Rudelle, an associate director of business development at ClinPhone.
A clear objective for ClinPhone has been to seek market opportunities and growth areas in Europe to specifically establish a first line physical presence. Having a local presence enables ClinPhone to provide increased face-to-face contact, trial consultations and expert advice in local languages.
“Customer service is a vital part of any successful business and ClinPhone prides itself on providing the best possible support to all of its clients regardless of location,” comments Steve Kent, chief executive officer, ClinPhone. “The opening of this new office is testament to our continued unwavering commitment and we are very excited about our expansion.”
ClinPhone has a comprehensive portfolio of clinical technology solutions, including its newly-launched DataLabs by ClinPhone (EDC) and ClinPhone Randomization and Trial Supply Management (IVR/IWR) integrated solution, electronic data capture (EDC), randomization, trial supply management, drug accountability, electronic patient reported outcomes (ePRO), clinical trial management systems (CTMS) and integration solutions. ClinPhone is the first company of its kind to offer such a comprehensive suite of software and services to the biopharmaceutical industry.
ClinPhone provides a range of clinical technology solutions to many of the world’s leading pharmaceutical and biotechnology companies. The company is the largest and most accomplished Clinical Technology Organization (CTO) in the industry, with experience in more than 2000 trials.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
